Gene delivery for immunoengineering

A growing number of gene delivery strategies are being employed for immunoengineering in applications ranging from infectious disease prevention to cancer therapy. Viral vectors tend to have high gene transfer capability but may be hampered by complications related to their intrinsic immunogenicity....

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in biotechnology 2020-12, Vol.66, p.1-10
Main Authors: Neshat, Sarah Y, Tzeng, Stephany Y, Green, Jordan J
Format: Article
Language:English
Subjects:
DNA
Gene Transfer Techniques
Genetic Therapy
Genetic Vectors
Nanoparticles
Transfection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c463t-4c8ca2ca80fa50c1f9dd65ebb2239c9db3293a64202483a54ddfb30477abc6143
cites cdi_FETCH-LOGICAL-c463t-4c8ca2ca80fa50c1f9dd65ebb2239c9db3293a64202483a54ddfb30477abc6143
container_end_page 10
container_issue
container_start_page 1
container_title Current opinion in biotechnology
container_volume 66
creator Neshat, Sarah Y
Tzeng, Stephany Y
Green, Jordan J
description A growing number of gene delivery strategies are being employed for immunoengineering in applications ranging from infectious disease prevention to cancer therapy. Viral vectors tend to have high gene transfer capability but may be hampered by complications related to their intrinsic immunogenicity. Non-viral methods of gene delivery, including polymeric, lipid-based, and inorganic nanoparticles as well as physical delivery techniques, have also been widely investigated. By using either ex vivo engineering of immune cells that are subsequently adoptively transferred or in vivo transfection of cells for in situ genetic programming, researchers have developed different approaches to precisely modulate immune responses. In addition to expressing a gene of interest through intracellular delivery of plasmid DNA and mRNA, researchers are also delivering oligonucleotides to knock down gene expression and immunostimulatory nucleic acids to tune immune activity. Many of these biotechnologies are now in clinical trials and have high potential to impact medicine.
doi_str_mv 10.1016/j.copbio.2020.05.008
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7313888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0958166920300720</els_id><sourcerecordid>32554325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-4c8ca2ca80fa50c1f9dd65ebb2239c9db3293a64202483a54ddfb30477abc6143</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gUjB866Tr93kIkjRKhS86Dlkk9ma0t2UbFvov3dLterFy8xheD_mIeSaQk6BFneL3MVVFWLOgEEOMgdQJ2RIVakzEEyfkiFoqTJaFHpALrpuAQCSl3BOBpxJKfoxJLdTbHHscRm2mHbjOqZxaJpNG7GdhxYxhXZ-Sc5qu-zw6muPyPvT49vkOZu9Tl8mD7PMiYKvM-GUs8xZBbWV4GitvS8kVhVjXDvtK840t4Xo-wrFrRTe1xUHUZa2cgUVfETuD76rTdWgd9iuk12aVQqNTTsTbTB_L234MPO4NSWnXCnVG4iDgUux6xLWRy0Fs4dmFuYAzeyhGZCmh9bLbn7nHkXflH6KYf_9NmAynQvYOvQhoVsbH8P_CZ8eIoCQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Gene delivery for immunoengineering</title><source>ScienceDirect Journals</source><creator>Neshat, Sarah Y ; Tzeng, Stephany Y ; Green, Jordan J</creator><creatorcontrib>Neshat, Sarah Y ; Tzeng, Stephany Y ; Green, Jordan J</creatorcontrib><description>A growing number of gene delivery strategies are being employed for immunoengineering in applications ranging from infectious disease prevention to cancer therapy. Viral vectors tend to have high gene transfer capability but may be hampered by complications related to their intrinsic immunogenicity. Non-viral methods of gene delivery, including polymeric, lipid-based, and inorganic nanoparticles as well as physical delivery techniques, have also been widely investigated. By using either ex vivo engineering of immune cells that are subsequently adoptively transferred or in vivo transfection of cells for in situ genetic programming, researchers have developed different approaches to precisely modulate immune responses. In addition to expressing a gene of interest through intracellular delivery of plasmid DNA and mRNA, researchers are also delivering oligonucleotides to knock down gene expression and immunostimulatory nucleic acids to tune immune activity. Many of these biotechnologies are now in clinical trials and have high potential to impact medicine.</description><identifier>ISSN: 0958-1669</identifier><identifier>EISSN: 1879-0429</identifier><identifier>DOI: 10.1016/j.copbio.2020.05.008</identifier><identifier>PMID: 32554325</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>DNA ; Gene Transfer Techniques ; Genetic Therapy ; Genetic Vectors ; Nanoparticles ; Transfection</subject><ispartof>Current opinion in biotechnology, 2020-12, Vol.66, p.1-10</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-4c8ca2ca80fa50c1f9dd65ebb2239c9db3293a64202483a54ddfb30477abc6143</citedby><cites>FETCH-LOGICAL-c463t-4c8ca2ca80fa50c1f9dd65ebb2239c9db3293a64202483a54ddfb30477abc6143</cites><orcidid>0000-0001-7849-5603</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32554325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neshat, Sarah Y</creatorcontrib><creatorcontrib>Tzeng, Stephany Y</creatorcontrib><creatorcontrib>Green, Jordan J</creatorcontrib><title>Gene delivery for immunoengineering</title><title>Current opinion in biotechnology</title><addtitle>Curr Opin Biotechnol</addtitle><description>A growing number of gene delivery strategies are being employed for immunoengineering in applications ranging from infectious disease prevention to cancer therapy. Viral vectors tend to have high gene transfer capability but may be hampered by complications related to their intrinsic immunogenicity. Non-viral methods of gene delivery, including polymeric, lipid-based, and inorganic nanoparticles as well as physical delivery techniques, have also been widely investigated. By using either ex vivo engineering of immune cells that are subsequently adoptively transferred or in vivo transfection of cells for in situ genetic programming, researchers have developed different approaches to precisely modulate immune responses. In addition to expressing a gene of interest through intracellular delivery of plasmid DNA and mRNA, researchers are also delivering oligonucleotides to knock down gene expression and immunostimulatory nucleic acids to tune immune activity. Many of these biotechnologies are now in clinical trials and have high potential to impact medicine.</description><subject>DNA</subject><subject>Gene Transfer Techniques</subject><subject>Genetic Therapy</subject><subject>Genetic Vectors</subject><subject>Nanoparticles</subject><subject>Transfection</subject><issn>0958-1669</issn><issn>1879-0429</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlb_gUjB866Tr93kIkjRKhS86Dlkk9ma0t2UbFvov3dLterFy8xheD_mIeSaQk6BFneL3MVVFWLOgEEOMgdQJ2RIVakzEEyfkiFoqTJaFHpALrpuAQCSl3BOBpxJKfoxJLdTbHHscRm2mHbjOqZxaJpNG7GdhxYxhXZ-Sc5qu-zw6muPyPvT49vkOZu9Tl8mD7PMiYKvM-GUs8xZBbWV4GitvS8kVhVjXDvtK840t4Xo-wrFrRTe1xUHUZa2cgUVfETuD76rTdWgd9iuk12aVQqNTTsTbTB_L234MPO4NSWnXCnVG4iDgUux6xLWRy0Fs4dmFuYAzeyhGZCmh9bLbn7nHkXflH6KYf_9NmAynQvYOvQhoVsbH8P_CZ8eIoCQ</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Neshat, Sarah Y</creator><creator>Tzeng, Stephany Y</creator><creator>Green, Jordan J</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7849-5603</orcidid></search><sort><creationdate>20201201</creationdate><title>Gene delivery for immunoengineering</title><author>Neshat, Sarah Y ; Tzeng, Stephany Y ; Green, Jordan J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-4c8ca2ca80fa50c1f9dd65ebb2239c9db3293a64202483a54ddfb30477abc6143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>DNA</topic><topic>Gene Transfer Techniques</topic><topic>Genetic Therapy</topic><topic>Genetic Vectors</topic><topic>Nanoparticles</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neshat, Sarah Y</creatorcontrib><creatorcontrib>Tzeng, Stephany Y</creatorcontrib><creatorcontrib>Green, Jordan J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current opinion in biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neshat, Sarah Y</au><au>Tzeng, Stephany Y</au><au>Green, Jordan J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gene delivery for immunoengineering</atitle><jtitle>Current opinion in biotechnology</jtitle><addtitle>Curr Opin Biotechnol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>66</volume><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0958-1669</issn><eissn>1879-0429</eissn><abstract>A growing number of gene delivery strategies are being employed for immunoengineering in applications ranging from infectious disease prevention to cancer therapy. Viral vectors tend to have high gene transfer capability but may be hampered by complications related to their intrinsic immunogenicity. Non-viral methods of gene delivery, including polymeric, lipid-based, and inorganic nanoparticles as well as physical delivery techniques, have also been widely investigated. By using either ex vivo engineering of immune cells that are subsequently adoptively transferred or in vivo transfection of cells for in situ genetic programming, researchers have developed different approaches to precisely modulate immune responses. In addition to expressing a gene of interest through intracellular delivery of plasmid DNA and mRNA, researchers are also delivering oligonucleotides to knock down gene expression and immunostimulatory nucleic acids to tune immune activity. Many of these biotechnologies are now in clinical trials and have high potential to impact medicine.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32554325</pmid><doi>10.1016/j.copbio.2020.05.008</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-7849-5603</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0958-1669
ispartof Current opinion in biotechnology, 2020-12, Vol.66, p.1-10
issn 0958-1669
1879-0429
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7313888
source ScienceDirect Journals
subjects DNA
Gene Transfer Techniques
Genetic Therapy
Genetic Vectors
Nanoparticles
Transfection
title Gene delivery for immunoengineering
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gene%20delivery%20for%20immunoengineering&rft.jtitle=Current%20opinion%20in%20biotechnology&rft.au=Neshat,%20Sarah%20Y&rft.date=2020-12-01&rft.volume=66&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0958-1669&rft.eissn=1879-0429&rft_id=info:doi/10.1016/j.copbio.2020.05.008&rft_dat=%3Cpubmed_cross%3E32554325%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c463t-4c8ca2ca80fa50c1f9dd65ebb2239c9db3293a64202483a54ddfb30477abc6143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32554325&rfr_iscdi=true